Aditxt is focused on bringing some of the most needed and promising health innovations and solutions to life in a faster, more efficient way using the power of precision medicine, precision diagnostics and monitoring, precision prevention, and precision treatment, offering an alternative to the one-size-fits-all approach to disease prevention, diagnostics, and treatment. The company's diverse innovation portfolio includes Adimune™, Inc., Adivir™, Inc., and Pearsanta™, Inc., which focus on retraining the immune system, treating infectious diseases, and offering high-quality lab testing, respectively. The diversity of the portfolio not only increases the potential for revenue generation but also reduces risk by not relying solely on one product or service.

Aditxt entered a definitive agreement to acquire EvoFem Biosciences, the creator of Phexxi, the first and only FDA-approved hormone-free contraceptive gel, in December 2023. Evofem posted $13.4 million in net sales of Phexxi in the first nine months of 2023 and is expected to report $18.1 to $18.3 million in net sales for fiscal 2023. The global non-hormonal birth control market was $27.7 billion in 2022 and is projected to grow to $52.2 billion by 2031.

Aditxt is also conducting a human clinical trial with Mayo Clinic, studying the central nervous system disorder Stiff-Person Syndrome using their proprietary ADI-100™. Mayo Clinic is currently working to enroll 15 to 20 patients, and initial screenings have begun, with dosing expected to begin in the near term.

Aditxt is executing a strategy designed to reach key clinical or commercial stages for its current programs and expand its portfolio to address additional markets, such as oncology and neurology, aligning with its goal for growth and diversification. The company completed a financing round in September 2023 that raised $10 million in gross proceeds, providing ample runway for the company to meet near-term milestones.

Monitoring our immune status enables more informed and timely health decisions:

• Everyone’s immune system is unique and responds differently to viruses, bacterial antigens, peptides, drugs, bone marrow, solid organ transplants and cancer.


• By measuring and monitoring each individual’s immune system, it unlocks a new universe of maintaining and treating our immune health. This is precision made possible.

Monitoring our immune status enables more informed and timely health decisions:

• Everyone’s immune system is unique and responds differently to viruses, bacterial antigens, peptides, drugs, bone marrow, solid organ transplants and cancer.
• By measuring and monitoring each individual’s immune system, it unlocks a new universe of maintaining and treating our immune health. This is precision made possible.

• Diverse product/service portfolio designed to bring promising health innovations and solutions to life faster and more efficiently
  • Aditxt combines expertise and resources spanning operations, finance, M&A, global partnerships, content and marketing, access to labs and research facilities, and more
• Adimune, Inc. focused on modulating the immune system to address autoimmunity, organ rejection, and allergies
  • Technology protected by 7 patent families with 8 US patents granted and 4 pending and 86 foreign patents granted and 14 pending
  • Recent notable licensing transactions in similar pre-Phase 3 assets generated upfront payments of $10M to $125M with total deal values exceeding $760M for each asset (source: Cortellis Health Intelligence)
• Definitive agreement to acquire Evofem Biosciences, creator of Phexxi®
  • Evofem achieved preliminary net sales of $18.1 to $18.3 million in 2023, up from $16.8 million in 2022
• Proprietary AditxtScore platform profiles immune system & monitors reactions to viruses, bacteria, allergens & transplanted organs
  • High-capacity CLIA-certified facility in Richmond capable of scaling to process 10M AditxtScore’s annually
• Building lab testing “anytime/anywhere” model through Pearsanta
  • Paradigm shift enabling consumers to access healthcare on demand
  • Market roll-out for at-home testing expected to begin in Q2 2024
  • Acquired proprietary Mitomic™ early disease and cancer detection platform in January 2024; platform targets liquid biopsy market which is expected to surpass $34.7 billion by 2030
  • Acquired proprietary EEG brain monitoring technologies (NeuroCap and NeuroEEG) for telehealth applications in January 2024; addresses market opportunity valued at $1 billion in 2022 and expanding at 10.2% CAGR through 2030
• Led by accomplished team with scientific and commercial experience spanning biotech startups, clinical trial design, and biopharma product development and marketing, and public company management

RedChip Investor Group Call with Aditxt (NASDAQ: ADTX)

Tuesday, January 16, 2024

Watch Replay Now